INmune Bio/INMB

$12.85

-1.98%
-
1D1W1MYTD1YMAX

About INmune Bio

INmune Bio, Inc. is a clinical-stage biotechnology pharmaceutical company. The Company is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient’s disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). It has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer’s and treatment resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.

Ticker

INMB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Raymond Tesi

Employees

10

Headquarters

Boca raton, United States

INmune Bio Metrics

BasicAdvanced
$232.84M
Market cap
-
P/E ratio
-$1.53
EPS
2.02
Beta
-
Dividend rate

What the Analysts think about INmune Bio

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
53.07% upside
High $22.00
Low $16.00
$12.85
Current price
$19.67
Average price target

INmune Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-8.5M
30.77%
Profit margin
0%
-

INmune Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 21.52%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.32
-$0.36
-$0.36
-$0.48
-
Expected
-$0.49
-$0.02
-$0.40
-$0.40
-$0.44
Surprise
-34.02%
1,700%
-9.24%
21.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell INmune Bio stock

Buy or sell INmune Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing